163 related articles for article (PubMed ID: 11993789)
1. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
[TBL] [Abstract][Full Text] [Related]
2. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
[TBL] [Abstract][Full Text] [Related]
3. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
[TBL] [Abstract][Full Text] [Related]
4. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Takenaka T; Itoh K; Suzuki T; Utsunomiya A; Matsuda S; Chou T; Sai T; Sano M; Konda S; Ohno T; Mikuni C; Deura K; Yamada T; Mizorogi F; Nagoshi H; Tomonaga M; Hotta T; Kawano K; Tsushita K; Hirano M; Shimoyama M;
Int J Hematol; 2004 Feb; 79(2):165-73. PubMed ID: 15005346
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group.
Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J
Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904
[TBL] [Abstract][Full Text] [Related]
7. [Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern].
Kamiya O; Hoshino A; Ohara K; Nagata K; Ono Y; Saito M; Itou T; Yamamoto K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):863-5. PubMed ID: 2469398
[No Abstract] [Full Text] [Related]
8. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy of multiple myeloma].
Uzuka Y; Saito Y; Ito T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944
[TBL] [Abstract][Full Text] [Related]
10. Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.
Shimizu K; Kamiya O; Hirabayashi N; Ichikawa A; Kawashima K; Kobayashi M; Mizuno H; Nagura E; Nitta M; Saito H; Sao H; Shibata T; Takeyama H
Jpn J Cancer Res; 1999 Mar; 90(3):355-60. PubMed ID: 10359052
[TBL] [Abstract][Full Text] [Related]
11. VAD followed by VMCP: an alternative regimen for multiple myeloma.
Wadhwa J; Kumar L; Kochupillai V
Med Oncol; 2002; 19(2):105-8. PubMed ID: 12180477
[TBL] [Abstract][Full Text] [Related]
12. [DAD, new intensive chemotherapy for patients with myeloma: a preliminary report].
Miwa H; Nagura E; Shimizu K; Nitta M; Ichikawa A; Ohno T; Kinoshita T; Shibata T; Sao H; Murase T; Takeyama H; Wakita A; Saito H;
Rinsho Ketsueki; 2002 Nov; 43(11):982-7. PubMed ID: 12508483
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
[TBL] [Abstract][Full Text] [Related]
14. Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.
Shimizu K; Kamiya O; Hamajima N; Mizuno H; Kobayashi M; Hirabayashi N; Takeyama H; Kato R; Kawashima K; Nitta M
Jpn J Cancer Res; 1990 Dec; 81(12):1320-7. PubMed ID: 2126002
[TBL] [Abstract][Full Text] [Related]
15. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
[TBL] [Abstract][Full Text] [Related]
17. Results and further perspectives of plasmocytoma chemotherapy.
Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
[TBL] [Abstract][Full Text] [Related]
18. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H
J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740
[TBL] [Abstract][Full Text] [Related]
19. Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden.
Hjorth M; Hellquist L; Holmberg E; Magnusson B; Rödjer S; Westin J
Br J Haematol; 1990 Feb; 74(2):185-91. PubMed ID: 2180471
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]